Office Location: Room B0884
Laboratory Website: ADD Program
2004-2008 Ph.D. University of Utah, Department of Pharmacology and Toxicology
1996-2001 B.S. University of Utah, Biology, Human Department and Family Studies, Salt Lake City, Utah
Preclinical analgesic and safety evaluation of the GalR2-preferring analog, NAX 810-2. Metcalf CS, Smith MD, Klein BD, McDougle DR, Zhang L, Bulaj G. Neurochem Res 2017, 42(7): 1983-1994.
Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP). Klein BD, Jacobson CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH. Neurochem Res 2017, 42(7): 1939-1948.
Development and pharmacological characterization of the rat 6 Hz model of partial seizures. Metcalf CS, West PJ, Thomson K, Edwards S, Smith MD, White HS, Wilcox KS. Epilepsia 2017, 58(6):1073-1084.
Efficacy of mGlu2-positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures. Metcalf CS, Klein BD, Smith MD, Pruess T, Ceusters M, Lavreysen H, Pype S, Van Osselaer, Twyman R, White HS. Epilepsia 2017, 58: 484-93.
Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics. Metcalf CS, Klein BD, McDougle DR, Zhang L, Kaufmann D, Bulaj G, White HS. Epilepsia 2017, 58: 239-246.
Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models. Metcalf CS, Klein BD, McDougle DR, Zhang L, Smith MD, Bulaj G, White HS. J Pharmacol Exp Ther. 2015, 352: 185-93.
Incorporation of monodisperse oligoethyleneglycol amino acids into anticonvulsant analogues of galanin and neuropeptide y provides peripherally acting analgesics. Zhang L, Klein BD, Metcalf CS, Smith MD, McDougle DR, Lee HK, White HS, Bulaj G. Mol Pharm. 2013, 10: 574-85
Methods for ECG evaluation of indicators of cardiac risk, and susceptibility to aconitine-induced arrhythmias in rats following status epilepticus. Bealer SL, Metcalf CS, Little JG. J Vis Exp. 2011 Apr 5; (50).
Autonomic and cellular mechanisms mediating detrimental cardiac effects of status epilepticus. Bealer SL, Little JG,Metcalf CS, Brewster AL, Anderson AE. Epilepsy Res. 2010, 91: 66-73.
Status epilepticus induces cardiac myofilament damage and increased susceptibility to arrhythmias in rats. Metcalf CS, Poelzing S, Little JG, Bealer SL. Am J Physiol Heart Circ Physiol. 2009, 297: H2120-7.
Status epilepticus produces chronic alterations in cardiac sympathovagal balance. Metcalf CS, Radwanski PB, Bealer SL. Epilepsia. 2009, 50: 747-54.
Differential regional effects of methamphetamine on dopamine transport. Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, Fleckenstein AE. Eur J Pharmacol. 2008, 590: 105-10.
Increased dietary sodium alters Fos expression in the lamina terminalis during intravenous angiotensin II infusion. Bealer SL, Metcalf CS, Heybore R. Exp Neurol. 2007, 204: 299-306.
Increased dietary sodium enhances activation of neurons in the medullary cardiovascular pathway during acute sodium loading in the rat. Bealer SL, Metcalf CS. Auton Neurosci. 2005, 117: 33-40.
Dr. Metcalf is a Research Assistant Professor in Pharmacology and Toxicology. He is also a Co-Investigator and the Associate Director of the Anticonvulsant Drug Development Program.
Dr. Metcalf’s primary research interests include the evaluation and advancement of novel therapies for the treatment of epilepsy. This work also involves ongoing efforts to identify and validate new seizure models that can be used to screen and differentiate lead compounds.
Approximately one-third of patients with epilepsy continue to have seizures despite treatment with one or more drugs. In addition, there are several special populations of epilepsy patients, including pediatric epilepsies and genetic syndromes, for which there are little or no effective therapies. Therefore, the development of new compounds for various forms of epilepsy is of critical importance for the ongoing treatment of epilepsy.
For several years, Dr. Metcalf has also been interested in the development of neuropeptide compounds for the treatment of epilepsy and pain. Both epilepsy and pain are conditions where currently available treatments are often inadequate for many patients, and novel targets for therapies such as neuropeptides may offer new therapeutic opportunities.
Dr. Metcalf’s work in this area has included both pre-clinical screening of novel compounds and the late-stage testing of lead candidate compounds. Dr. Metcalf’s ongoing work in this area includes testing of analogs of the neuropeptide galanin, alone and in combination with other drugs, in models of epilepsy and pain, in order to identify a lead compound for progression into clinical testing.
Finally, Dr. Metcalf is also interested in the mechanisms of and potential clinical interventions for sudden unexpected death in epilepsy (SUDEP). While it is known that individuals with epilepsy, and particularly those with poorly controlled seizures, are at an increased risk for SUDEP, the mechanisms for this condition are not well understood. Therefore, understanding of risk factors, biomarkers, and potential clinical interventions to prevent SUDEP are an area of unmet need in epilepsy.
Bealer SL, Metcalf CS, Poelzing S, Little JG, Brewster A, Anderson A. Cardiac myocyte damage, electrocardiographic dysfunction, and ion channel remodeling in rodent models of seizure disorders In Schachter SC (Ed.) Sudden Unexpected Death in Epilepsy: Mechanisms and New Methods for Analyzing Risks (pp. 235-240). Boca Raton, FL: CRC Press, Taylor & Francis Group.
Bealer SL, Metcalf CS, Little JG, Vatta M, Brewster A, Anderson AE (2011). Sympathetic nervous system dysregulation of cardiac function and myocyte potassium channel remodeling in rodent seizure models: candidate mechanisms for SUDEP In Leetsma JE (Ed.) Sudden Death in Epilepsy: Forensic and Clinical Issues (pp. 615-626). Boca Raton, FL: CRC Press, Taylor & Francis Group.